Borayer Raises ￥100 million in Extended Series B Round

(VCBeat) July. 12, 2021 -- Jiangxi Borayer Biotechnology Co., Ltd. ("Borayer"), a leader in the field of biological materials, announced the completion of an extended Series B financing of nearly RMB 100 million, led by Matrix Partners China, with participation from DT Capital Partners, and the existing investor YuanBio Venture Capital. WinX Capital served as the lead financial adviser for the round.

Borayer, founded by a team graduated from Tsinghua University with the mission to bring Tissue Regeneration into reality, focusing on the research, development and production of cutting-edge biomaterials. Borayer provides clinical medicine with series of high-end medical consumables for rapid hemostasis, wound repair and tissue regeneration. The company has established several leading technology platforms of polymeric biomaterials, together with top universities, research institutes and Grade-A hospitals. It is committed to the continuous development of high-end medical devices and valuable medical solutions.

In the blue ocean market of biomedical materials, with its innovative R&D strength of core team and leading biomaterial technology platform, Borayer has developed medical adhesives, fluid hemostatic agents, degradable nasal sponges, and other products. The company also has dozens of projects under development.

In terms of technology platform, Borayer has built up a number of leading biomaterial technology platforms, covering biological polysaccharides, protein extracts, acrylic compounds, degradable polyurethane and polyethylene glycol derivatives, and has continuously formed a rich product pipeline for different types of tissues in the human body based on those platforms.

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant industry-leading companies. Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have gone on to profitable M&A events. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

Founded in 2006 and based in Shanghai, China, DT Capital Partners is a private equity investment firm that provides growth capital to companies in the early and growth stage. They invest in dynamic businesses that have high growth potential, strong management teams, and demonstrated revenue models in both technology-based and traditional industries.